Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and Hormone Therapy in Advanced Breast Cancer with Quantum Optics Analysis
NCT05190094Phase 2Recruiting
- Sponsor
- International Cancer Research Group
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in breast cancer, sponsored by International Cancer Research Group. Primary endpoints: Rate of Objective Clinical Response at 2 years and Sensitivity and Specificity of prediction of the efficacy at 2 years. Started Dec 2022; status: recruiting.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05190094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05190094.